Graham Hoffman, a 29-year-old paramedic at the Missouri Fire Department, passed away on Sunday following a fatal stabbing by a patient. Authorities announced that after a medical call came in, Hoffman was accompanying the patient to a nearby hospital.

The Economist/YouGov poll found that 87% of Democrats want Abrego Garcia to return to the United States. The question to survey respondents was: “The Trump administration recently deported Kilmar Abrego Garcia to El Salvador despite a court order prohibiting his deportation. Do you believe Trump should bring Abrego Garcia back to the U.S.?” The phrasing is […] The post New Poll on Returning the Maryland Dad to the US appeared first on www.independentsentinel.com.

'Do not sufficiently comply'

This Story About an Alabama Abortion Clinic is Supposed to Be Sad

Student loans are back in the headlines as the Trump administration moves to resume collections on delinquent federal student debt.The issue demands serious scrutiny. Borrowers should honor their obligations. Yet the federal government has become the world’s largest predatory lender, handing tens of thousands of dollars in debt to teenagers who often lack the financial literacy to understand what they are signing. No underwriting process checks their ability to repay. Unlike most other loans, student debt cannot be discharged through bankruptcy.The Trump administration should shift its collection stance and seize the opportunity to reform the broken student lending system.This corrupt setup has enriched colleges, universities, and their administrators while leaving young people burdened with worthless degrees and mountains of debt.With an entire generation saddled by debt and losing faith in the American dream, the Trump administration should lead a bold reform effort to fix student lending.A five-step planFirst, Trump should work with Congress to get the federal government out of the student loan business entirely. The government is not a bank. Borrowing money at the federal level only to shovel it out to unqualified borrowers is reckless and unsustainable.Next, the administration should pressure universities — particularly nonprofits with massive endowments. To maintain their tax-exempt status, these institutions must justify the return on investment for their degrees, hold a stake in the loans, and offer refunds for programs that fail to deliver promised outcomes.If a student pursues a degree leading to a $50,000 salary, a college should warn them that taking on $200,000 in debt will never produce a worthwhile return. Aligning financial incentives would push schools to prioritize real-world job skills over administrative bloat and ideological indoctrination.Student loans should also undergo an underwriting process based on both the student’s academic aptitude and the projected market value of the degree they are pursuing. Loans for high-value degrees should be higher than those for low-value ones, forcing colleges to stay competitive. Loans should also be restricted from funding noneducational expenses like spring break trips.Additionally, student loans should become dischargeable through bankruptcy, just like other forms of personal debt. Colleges that hold a portion of the loan would then share the risk, giving them a stake in student success.Finally, outstanding student loans must be restructured. Interest payments already made should be applied toward the principal, and students should have the right to seek recourse against universities that saddled them with overpriced, low-value degrees.Trump’s big opportunityThe Trump administration has already welcomed many young Americans into the center-right coalition. Tackling the real crisis of college debt — an industry siphoning wealth from the next generation while pretending to offer economic opportunity — would show young voters that conservatives stand for their future. Fixing student lending is not only good politics; it is the right thing to do to preserve the American dream for everyone.

Progressives routinely advance their agenda by obscuring the suffering of women and children. Every cultural revolution they champion, from redefining marriage to dismantling biological sex to flooding the country with abortion pills, demands one thing: suppression of consequences. During the gay marriage debate, we were told it was all about adult love and equality. In reality, children paid the price. This is the progressive playbook: Minimize harm, deny casualties, and move the Overton window. With the transgender surge, Americans were assured it was just about “letting people pee in peace.” In reality, it meant lost female swim and track records, male rapists in women’s prisons, and irreversible surgeries on minors. And now it's the abortion pill. Sold as “a safe, effective, FDA-approved method for people to end a pregnancy in the comfort of their own homes,” it has quietly become one of the most dangerous medical products routinely given to American women — no doctor visit required. A groundbreaking new study by the Ethics and Public Policy Center shatters the illusion of safety around mifepristone, the abortion drug created by Danco Laboratories and greenlighted by the FDA. Based on real-world insurance claims (versus the previous shallow clinical trials) the data shows that one in 10 women who take the abortion pill suffer a serious or life-threatening complication: sepsis, hemorrhaging, emergency surgery, hospitalization — even death. “Simply stated,” the report says, “mifepristone, as used in real-world conditions, is not ‘safe and effective.’” Naming the victims The study analyzed a staggering 865,727 chemical abortions between 2017 and 2023, drawn from an all-payer insurance claims database covering private insurers, Medicaid, Medicare, Tricare, and the Department of Veterans Affairs. Unlike the cherry-picked participants in controlled trials, these women represent the actual population using mifepristone today. The EPPC found that 10.93% of women experienced serious adverse events within 45 days of their abortions — a rate 22 times higher than what the FDA reports on its drug label, which still cites outdated trials from as far back as 1983. As the authors note, those clinical trials enrolled just 30,966 people and were conducted under tightly controlled conditions. The real world doesn’t work that way. And the real world has already buried the dead. Amber Nicole Thurman, a 28-year-old medical assistant and mother from Georgia, died on August 19, 2022, from septic shock after experiencing complications from a medication abortion. After taking abortion pills, she developed a severe infection due to retained fetal tissue. In 2017, 23-year-old Keisha Atkins underwent a late-term abortion in New Mexico, using mifepristone and misoprostol. She developed sepsis and required transfer to the University of New Mexico Hospital. Her condition rapidly worsened, and she died during emergency surgery.Atkins and Thurman are not rare exceptions. Candi Miller, a 41-year-old mother, and Porsha Ngumezi, 35, also suffered fatal complications. Other unnamed victims fill the record. These women represent just a fraction of the tens of thousands who faced serious complications after taking mifepristone. The EPPC report confirms what these stories reveal: The FDA has abandoned its responsibility to women in pursuit of politically pressured expediency. In the name of “access,” the FDA has dismantled the original safeguards it once demanded when approving mifepristone in 2000. Back then, patients were required to make three in-person visits. Only physicians could prescribe the drug. Pills had to be administered in a clinic or hospital setting. Providers had to be able to diagnose ectopic pregnancies and provide emergency surgical care if needed. Adverse events had to be reported. Now? One telehealth call. Pills mailed to your house. And no obligation to report complications — unless the woman dies. Returning to reality In light of such overwhelming evidence of harm, the EPPC report recommends that “the FDA immediately reinstate its earlier, stronger patient safety protocols to ensure physician responsibility for women who take mifepristone under their care, as well as mandate full reporting of its side effects.” The EPPC is right. Because the data is damning. The study used the FDA’s own criteria to identify serious adverse events: infections, transfusions, ER visits, repeat surgeries, and psychiatric emergencies, all coded through ICD-10 and CPT medical billing systems. And while the report was cautious — tracking events within 45 days instead of the 72-day window used by FDA trial data — the outcome was still catastrophic. “We included CTCAE Grade 3 (severe) and Grade 4 (life-threatening),” the report notes. “We did not include Grade 1 (mild) or Grade 2 (moderate).” In other words, these weren’t headaches or stomach cramps. These were emergencies. And the women were often alone. Chemical abortions now account for roughly two-thirds of all abortions in America. That means mifepristone is not a niche product — it’s mainstream. And yet the public has been systematically lied to about the risks, even as the federal government continues to loosen restrictions. This is the progressive playbook: Minimize harm, deny casualties, and move the Overton window. It worked with marriage. It worked with gender. It’s working with abortion pills — unless we stop pretending. Justice requires living in reality. And the reality is that women and children are the consistent casualties of the progressive utopia. We owe women more than euphemisms about “empowerment.” We owe them truth, compassion, accountability — and, in this case, stricter regulations that once existed for their protection. The EPPC’s report is only the beginning. As more real-world data emerges, the FDA and drug manufacturers will be forced to answer the one question they’ve dodged for decades: How many women must suffer and die before “safe and effective” actually means something again?

Houthis Trigger $56M Loss: US Fighter Jet Sinks in Red Sea While Evading Drone and Missile Attack

Rachel Maddow Tells Viewers Trump Is Taking Away Narcan